Use of Amino Acids for Making Medicines for Treating Insulin Resistance

Abstract

The invention concerns the use of monohydroxy or polyhydroxy amino acids, and the lactone forms thereof for making medicines with insulin-analogue and/or insulin-sensitizing effects on peripheral tissues targeted by insulin, and more particularly the use thereof for making medicines for treating and preventing insulin-resistance.

1 ) Use of a compound chosen from the group constituted by mono-hydroxylated amino acids, poly-hydroxylated amino acids, and the lactonic forms of these acids, for the manufacture of a medicament with insulin mimetic and/or insulin-sensitizing effects. 
   
   
       2 ) Use according to  claim 1 , characterised in that said medicament is intended to exercise an insulin mimetic and/or insulin-sensitizing effect at the level of the peripheral target tissues of insulin. 
   
   
       3 ) Use according to  claim 1  or  2 , characterised in that said compound reduces phosphatase activity associated with the signalling route of the insulin receptor, and/or stimulates PI 3-kinase activity on IRS-1 and/or IRS-2. 
   
   
       4 ) Use according to any one of the previous claims, characterised in that said compound is 4-hydroxyisoleucine of formula 
     
       
         
         
             
             
         
       
     
     and/or the lactonic form of this amino acid. 
   
   
       5 ) Use according to  claim 4 , characterised in that 4-hydroxyisoleucine is presented in the form of its 2S, 3R, 4S isomer or the corresponding lactone. 
   
   
       6 ) Use according to any one of  claims 1  to  5 , for the manufacture of a medicament intended for the treatment of insulin resistance. 
   
   
       7 ) Use according to any one of  claims 1  to  6 , for the manufacture of a medicament intended to combat the syndromes associated with insulin resistance. 
   
   
       8 ) Use according to any one of  claims 1  to  7 , for the manufacture of a medicament against hyperinsulinemia. 
   
   
       9 ) Use according to any of  claims 1  to  7 , for the manufacture of a medicament against insulin resistance associated with ageing. 
   
   
       10 ) Use of any one of  claims 1  to  7 , for the manufacture of a medicament against illnesses associated with obesity. 
   
   
       11 ) Use according to any one of  claims 1  to  7 , for the manufacture of a medicament intended to inhibit the proliferation of cell lines associated with the risk of the appearance of cancer. 
   
   
       12 ) Use according to any one of  claims 1  to  5 , for the manufacture of a medicament intended for the prevention of insulin resistance. 
   
   
       13 ) Use according to any one of  claims 1 - 5 , and  12 , for the manufacture of a medicament intended to reduce the need for exogenic insulin. 
   
   
       14 ) Pharmaceutical composition or kit comprising both insulin and a compound chosen from the group constituted by mono-hydroxylated amino acids, poly-hydroxylated amino acids, and the lactonic forms of these acids.